Core Insights - Eton Pharmaceuticals has acquired Galzin® (zinc acetate), a medication for Wilson Disease, enhancing its portfolio in rare disease treatments [1][2][7] - The acquisition aligns with Eton's mission to support life-saving treatments for ultra-rare patient populations [2] Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering six commercial products and four additional candidates in late-stage development [12] Product Details - Galzin is FDA-approved for maintenance treatment of Wilson Disease patients who have been initially treated with a chelating agent, with an estimated patient population of less than 5,000 in the U.S. [3][4] - Eton plans to commercialize Galzin in the U.S. in Q1 2025, supported by its metabolic sales force and the Eton Cares patient support program [4] Patient Support Program - The Eton Cares program will provide a $0 co-pay for qualified commercial patients, prescription fulfillment, insurance benefits investigation, and educational support [4] European Rights - Eton has acquired European rights to Galzin, where it is marketed as Wilzin® by a third party, with Eton continuing to supply the product under an existing distribution agreement [5]
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®